![A Strategy to Minimize Reactive Metabolite Formation: Discovery of (
<i>S</i>
)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist
<sup>†</sup>]()
A Strategy to Minimize Reactive Metabolite Formation: Discovery of (
<i>S</i>
)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist
<sup>†</sup>Hartz, Richard A.; Ahuja, Vijay T.; Zhuo, Xiaoliang; Mattson, Ronald J.; Denhart, Derek J.; Deskus, Jeffrey A.; Vrudhula, Vivekananda M.; Pan, Senliang; Ditta, Jonathan L.; Shu, Yue-Zhong; Grace, James E.; Lentz, Kimberley A.; Lelas, Snjezana; Li, Yu-Wen; Molski, Thaddeus F.; Krishnananthan, Subramaniam; Wong, Henry; Qian-Cutrone, Jingfang; Schartman, Richard; Denton, Rex; Lodge, Nicholas J.; Zaczek, Robert; Macor, John E.; Bronson, Joanne J. · Journal of Medicinal Chemistry · 2009